Histoplasmosis is a systemic mycosis frequently affecting patients infected with HIV, appearing as acute or subacute disseminated forms. Early diagnosis is simple when muco-cutaneous lesions are present; but in their absence the use of non-culture based methods is usually required presenting a fundamental challenge for the management and prognosis of this infection. The aim of this study was to analyze the sensitivity and specificity of an Elisa kit for the detection of the galactomannan antigen of Histoplasma capsulatum in different clinical samples. A total of 98 clinical samples obtained from different organic fluids were analyzed: 66 sera, 28 urine samples, 3 bronchoalveolar lavages and one cerebrospinal fluid. They corresponded to a total of 61 patients: 27 with histoplasmosis associated with AIDS, 7 histoplasmosis in nonreactive HIV individuals and 27 patients with other diseases but which were clinically similar to histoplasmosis. The sensitivity of the detection of the galactomannan antigen in serum of patients with histoplasmosis and AIDS was 76% and the specificity was 56%. In urine samples of this group of patients the sensitivity was 75%.
INTRODUCTION
Histoplasmosis is a systemic mycosis that frequently affects HIVinfected individuals and is the third most frequent mycosis in Argentina in this population. This group of patients usually suffers acute or sub-acute disseminated forms. When cutaneous or muco-cutaneous lesions are present (> 60% of cases in our country) early diagnosis is facilitated since it is possible to visualize yeasts in direct examinations of samples obtained by scraping these lesions. However, there is a percentage of patients without muco-cutaneous manifestations and whose symptoms are similar to those of many other AIDSrelated infections. In such cases the diagnosis is often reached from the blood cultures, but this requires considerable time and early mortality in untreated patients is very high (30%) (Cáceres et al. 2016 ; Colombo et al. 2011; Negroni 2008 ).
Recently, ELISA techniques for the detection in urine or serum of circulating antigens of Histoplasma capsulatum have been developed with promising results ; Hage et al. 2011; Wheat et al. 1986 ). However, they are only available in the USA. Several researchers have developed other immunoenzymatic techniques and the Center for Disease Control (CDC) has standardized a kit which was validated both in Guatemala and Colombia (Cáceres et The aim of this study was to analyze the sensitivity and specificity of an ELISA kit for the diagnosis of histoplasmosis by detection of the galactomannan antigen of H. capsulatum in different clinical samples of patients with histoplasmosis, especially when this mycosis was associated with AIDS.
MATERIAL AND METHODS
A total of 98 samples of different organic fluids were analyzed: 66 sera, 28 urine samples, 3 bronchoalveolar lavages and one cerebrospinal fluid. They corresponded to a total of 61 patients: 27 with histoplasmosis associated with AIDS, 7 cases of progressive histoplasmosis not related to AIDS and 27 patients with other diseases that were clinically similar to histoplasmosis and which were evaluated to study the specificity of the test (control group).
Histoplasmosis has been confirmed in all cases by direct examination or cultures of different clinical samples according to the methodology routinely used in the Mycology Unit (Arechavala et al. 1993; Bianchi et al. 2000; Guelfand et al. 2015) (Tables 1 and 2) . Serological tests (immunodiffusion and counter immunoelectrophoresis) for detection of anti-H. capsulatum antibodies were applied to all the sera used for the detection of the galactomannan antigen (Guelfand et al. 2015) .
Determinations to detect H. capsulatum galactomannan antigen were performed by ELISA, IMMY ALPHA® (Immunomycologics, Norman, Ok. USA). The total number of determinations was very limited as we only had a single kit. This was provided by the manufacturers to test the methodology, as it is not commercially available in our country yet. Determinations in serum were performed in the same way as in urine samples, EDTA or heat were not used to pre-treat the serum samples to break immune complexes, as has been reported in other papers (Swartzentruber et al. 2009a ). In the group of histoplasmosis in HIV negative patients the detection of the antigen was done at the moment of the diagnosis in 6 cases and in a posttherapeutic control in 2 patients (Table 1) . In all cases the determination was performed in serum and in 2 patients it was also fulfilled in urine.
In the group of patients with histoplasmosis and AIDS the determinations were made at the time of diagnosis in 26 cases and in one case it was performed in a patient who had suffered the disease two years earlier. This individual was undergoing an immune reconstitution inflammatory syndrome with presence of yeasts compatible with H. capsulatum in a lymph node sample obtained by puncture but whose culture was negative. In 4 cases further determinations were made during follow-up and in one case only in a treatment control.
RESULTS

Histoplasmosis in HIV-negative patients
Serological tests were positive in 6/7 cases at the moment of diagnosis of histoplasmosis but the detection of antigenemia was positive only in 2/6 sera (33.3%) and in 1/2 of the analyzed urine samples. The concentration of galactomannan antigen in the positive samples was low and ranged from 0.57 to 4.54 ng/ml. The results of the studies performed on HIV-negative patients with histoplasmosis are shown in Table 1 .
Histoplasmosis in HIV-positive patients
The results were positive in 25/33 sera, 18/24 urine samples, and 2/3 bronchoalveolar lavages. Some negative antigenemia results corresponded to sera from patients with positive antigenuria and others to post-treatment controls and only 3 patients were negative at the time of diagnosis. Eight out of 10 patients with positive serology results showed the presence of galactomannan antigen in serum or urine. The antigen concentration in the 2 positive bronchoalveolar lavages was very high (46 and 38.9 ng/ml). The data corresponding to the group of patients with histoplasmosis associated with AIDS is presented in table 2.
Controls
Fourteen serum and two urine samples were negative. In the 11 positive samples antigen levels varied between 0.75 and 2.65 ng/ml except in one case of chronic pulmonary aspergillosis where the value was 14.59 ng/ml. The results of antigen detection in serum and urine of patients suffering from other conditions different from histoplasmosis used as controls are presented in Table 3 . Histoplasma capsulatum antigens that are released from the fungal cells can be detected in several body fluids (serum, bronchoalveolar lavage, pleural fluid, cerebrospinal fluid and urine) . In order to improve and accelerate the diagnosis of histoplasmosis, especially in HIVpositive patients, techniques for the detection of circulating antigens were implemented many years ago. The first method applied was a radioimmunoassay technique described in 1986, which was only performed in Indianapolis (USA) (Wheat et al. 1986 Numerous studies have demonstrated that the ELISA technique has a high sensitivity to detect antigens in urine and also in serum. However crossreactions may occur, especially when tested on materials from patients with other systemic mycoses (specificity in that group ranges between 10 and 31%) (Assi et In this study, the sensitivity of the detection of the galactomannan antigen in serum of patients with histoplasmosis and AIDS was 76% and in urine was 75%, and the specificity in serum was 56%. Only 2 determinations were made in urine in the control group that resulted negative.
The sensitivity of the technique with serum samples was lower in HIV-negative patients with chronic forms of histoplasmosis. In 6/7 cases antibodies were detected by immunodiffusion. Some authors demonstrated that the sensitivity of the detection of circulating antigen might be increased by breaking the immune complexes with EDTA and/or heat (Swartzentruber et al. 2009a ). Since we only had one kit to perform the technique, it was not simultaneously tested in sera treated with EDTA.
The technique was only tested in 3 bronchoalveolar lavage samples in patients with AIDS-associated histoplasmosis. In two, a very high value of antigen was detected which is in agreement with that reported in other publications (Hage et As in other publications some cross-reactions were detected, the highest value was for a patient with chronic pulmonary aspergillosis (14.6 ng/ ml). Another case with pneumocystosis had positive antigenemia as well as one with leishmaniasis and in a patient with lung cancer. One patient with a urinary candidiasis showed a negative result. Theel et al. (2013) have evaluated this equipment and compared it with the one developed in Indianapolis (MiraVista) used as reference. 1003 samples of urine were processed in parallel and the results were concordant in 939 samples that were negative and 40 samples that were positive. Two samples were false positive with the IMMY kit and 45% of the remaining 22 that had been positive only with the MiraVista kit had values <0.4 ng/ml (Theel et al. 2013; Theel et al. 2015) .
Despite the fact that the number of patients is low, we observed that this rapid technique contributes to the diagnosis of AIDS-related histoplasmosis. Galactomannan antigen levels were very high in urine although in some cases the determination was positive in serum and not in urine. It would be of great interest to be able to increase the number of samples to present more consistent data, especially referring to the specificity. It would also be of value to test with sera treated with EDTA and heat to observe if breaking the immune complex increases the sensitivity of this technique.
